Company Description
Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. It engages in novel products development used in PRINT technology to transform the lives of patients. PRINT is a particle engineering platform that enables ...
Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. It engages in novel products development used in PRINT technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. The company was founded on June 28, 2020 and is headquartered in Morrisville, NC.
Valuation
Price to Sales Ratio
15.60
Price to Book Ratio
3.90
Enterprise Value to EBITDA
-15.33
Enterprise Value to Sales
31.03
Efficiency
Total Asset Turnover
0.16
Liquidity
Current Ratio
8.36
Quick Ratio
8.36
Cash Ratio
7.85
Profitability
Gross Margin
53.42
Operating Margin
-217.94
Pretax Margin
-222.98
Net Margin
-222.98
Return on Assets
-35.06
Return on Equity
-50.72
Return on Total Capital
-39.86
Capital Structure
Total Debt to Total Assets
16.71
Officers and Executives
| Name | Age | Officer Since | Title |
|---|---|---|---|
| Dr. Roger A. Jeffs | 59 | 2020 | Independent Director |
| Mr. Robert A. Lippe | 55 | 2020 | Chief Operating Officer |
| Mr. Michael Kaseta | 45 | 2020 | Chief Financial Officer |
| Mr. Scott Moomaw | 51 | 2020 | Senior Vice President-Commercial |
Insider Actions
| 07/18/2022 |
Rajeev Saggar Chief Medical Officer |
93,834 | Award at $0 per share. | 0 |
| 05/31/2022 |
Michael Kaseta Chief Financial Officer |
5,061 | Acquisition at $4 per share. | 20,244 |
| 05/31/2022 |
Michael Kaseta Chief Financial Officer |
13,639 | Acquisition at $4.01 per share. | 54,692 |
| 05/25/2022 |
Caligan Partners LP Director |
79,400 | Acquisition at $3.4 per share. | 269,960 |
| 05/24/2022 |
Roger A. Jeffs Chief Executive Officer; Director |
28,000 | Acquisition at $3.53 per share. | 98,840 |
| 05/24/2022 |
Robert A. Lippe Chief Operations Officer |
29,628 | Acquisition at $3.38 per share. | 100,142 |
| 05/19/2022 |
Caligan Partners LP Director |
85,000 | Acquisition at $5.81 per share. | 493,850 |
| 05/18/2022 |
Caligan Partners LP Director |
76,404 | Acquisition at $5.89 per share. | 450,019 |
| 05/17/2022 |
Caligan Partners LP Director |
59,700 | Acquisition at $5.99 per share. | 357,603 |
| 04/18/2022 |
Caligan Partners LP Director |
1,764,705 | Acquisition at $5.1 per share. | 8,999,995 |
| 04/18/2022 |
Paul B. Manning Director |
392,156 | Acquisition at $5.1 per share. | 1,999,995 |
| 03/31/2022 |
Roger A. Jeffs Chief Executive Officer; Director |
154,167 | Award at $0 per share. | 0 |
| 03/31/2022 |
Russell T. Schundler General Counsel |
2,158 | Award at $0 per share. | 0 |
| 03/31/2022 |
Damian deGoa Director |
4,625 | Award at $0 per share. | 0 |
| 11/12/2021 |
Robert A. Lippe Chief Operations Officer |
518 | Derivative/Non-derivative trans. at $5.04 per share. | 2,610 |
| 11/12/2021 |
Robert A. Lippe Chief Operations Officer |
12,612 | Derivative/Non-derivative trans. at $4.9 per share. | 61,798 |
| 11/12/2021 |
Tushar Shah CMO and Head of R&D |
11,882 | Derivative/Non-derivative trans. at $4.9 per share. | 58,221 |
| 11/12/2021 |
Tushar Shah CMO and Head of R&D |
487 | Derivative/Non-derivative trans. at $5.04 per share. | 2,454 |
MarketWatch News on LQDA
-
Liquidia stock price target cut to $4 from $6 at Wedbush
- Tomi Kilgore
-
Liquidia stock price target cut to $4 from $20 at Wedbush
- Tomi Kilgore
-
Liquidia downgraded to neutral from outperform at Wedbush
- Tomi Kilgore
-
Liquidia Technologies stock price target lowered to $37 vs. $50 at Wedbush
- Ciara Linnane
Other News on LQDA
-
Why Liquidia Shares Rose 18.4% on Monday
- Motley Fool
-
BBBY, CBAT and DOYU are among pre market gainers
- Seeking Alpha
-
- Edgar Online - (EDG = 10Q, 10K)
-
Notable earnings before Thursday's open
- Seeking Alpha
-
Liquidia Vs. MannKind: Treprostinil Is The Big 'IF'
- Seeking Alpha
-
Liquidia added to Russell 2000 and 3000 Indexes
- Seeking Alpha
-
Why Liquidia Stock Rose as Much as 22% Higher Today
- Motley Fool
- Loading more headlines...
